等待开盘 11-19 09:30:00 美东时间
-0.010
-0.10%
华盛资讯11月6日讯,Intellia Therapeutics, Inc.公布2026财年Q3业绩,公司Q3营收0.07亿美元,同比下降48.0%,归母净利润亏损1.27亿美元,同比亏损扩大25.8%。
11-06 10:46
Intellia Therapeutics (NASDAQ:NTLA) reported quarterly losses of $(0.91) per share which missed the analyst consensus estimate of $(0.80) by 15.19 percent. This is a 1.09 percent increase over losses of $(0.92) per share from the same period last year. The company reported quarterly sales of $7.163 ...
11-05 21:41
华盛资讯11月5日讯,Intellia Therapeutics, Inc.公布2026财年Q3业绩,公司Q3营收0.07亿美元,同比下降48.0%,归母净利润亏损1.27亿美元,同比亏损扩大25.8%。
11-05 21:35
Pacira BioSciences暴升44%,获Viatris16.5亿美元收购;Haemonetics升逾17%,CSL拟于27年底前部署NexSys PCS血浆采集设备>>
10-09 18:33
今日重点评级关注:Jones Trading:维持Opus Genetics"买入"评级,目标价从10美元升至17美元;Citizens:维持Rezolute"跑赢大市"评级,目标价从11美元升至15美元
10-07 17:30
Barclays analyst Gena Wang initiates coverage on Intellia Therapeutics (NASDAQ:NTLA) with a Underweight rating and announces Price Target of $8.
10-06 20:09
今日重点评级关注:富国银行:维持Pyxis Oncology"超配"评级,目标价从12美元升至19美元;Oppenheimer:维持Opus Genetics"跑赢大市"评级,目标价从10美元升至20美元
09-10 15:00
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that it has entered into a $400 million non-dilutive senior secured term loan facility with OrbiMed, a leadin...
09-04 20:51
今日重点评级关注:摩根大通:维持Ultragenyx Pharmaceutical"超配"评级,目标价从75美元升至80美元;瑞杰金融:维持英伟达"强力买入"评级,目标价从330美元升至352美元
08-26 08:37
Citizens analyst Silvan Turkcan reiterates Intellia Therapeutics (NASDAQ:NTLA) with a Market Outperform and maintains $30 price target.
08-25 21:18